On October 6, PHARMARON rose 3.29% in regular trading, trading at HK$32.66/share, with turnover of HK$22.28 million.
This follows JPMorgan Chase & Co.’s acquisition of 3.18 million shares at approximately HK$30.33 per share on September 29, raising their beneficial ownership from 14.43% to 15.31%. Such institutional stake-building often signals confidence in the company’s growth prospects, particularly after PHARMARON reported 17.9% year-over-year revenue growth for the first half of 2026.
The Life Sciences Tools & Services sector showed mixed movement today: WUXI BIO up 4.33%, GENSCRIPT BIO up 5.57%, WUXI APPTEC up 1.51%, XTALPI up 4.46%, INSILICO up 4.56%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)